Cancer Immunotherapy with Cytokine-Induced Killer Cells

Cytokine-induced killer (CIK) cells form under certain stimulation conditions in cultures of peripheral blood mononuclear cells (PBMCs). They are a heterogeneous immune cell population and contain a high percentage of cells with a mixed T-NK phenotype (CD3+CD56+). The ready availability of a lymphoc...

Full description

Saved in:

Bibliographic Details
Published in:	Targeted oncology Vol. 12; no. 3; pp. 289 - 299
Main Authors:	Mata-Molanes, Juan J., Sureda González, Manuel, Valenzuela Jiménez, Belén, Martínez Navarro, Elena Mª, Brugarolas Masllorens, Antonio
Format:	Journal Article
Language:	English
Published:	Cham Springer International Publishing 01-06-2017 Springer Nature B.V
Subjects:	Animals Biomedicine Cancer Vaccines - immunology CD3 Complex - metabolism CD56 Antigen - metabolism Clinical trials Clinical Trials as Topic Cytokine-Induced Killer Cells - immunology Cytokine-Induced Killer Cells - transplantation Cytokines Cytotoxicity, Immunologic Drug Resistance, Neoplasm Histocompatibility Antigens Class I - metabolism Humans Immunotherapy Immunotherapy, Adoptive - methods Medicine Medicine & Public Health Neoplasm Staging Neoplasms - immunology Neoplasms - therapy NK Cell Lectin-Like Receptor Subfamily K - metabolism Oncology Review Article Signal Transduction T cell receptors Targeted cancer therapy Tace Overall Response Rate Bispecific Antibody Oncolytic Adenovirus Overall Survival
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Cytokine-induced killer (CIK) cells form under certain stimulation conditions in cultures of peripheral blood mononuclear cells (PBMCs). They are a heterogeneous immune cell population and contain a high percentage of cells with a mixed T-NK phenotype (CD3+CD56+). The ready availability of a lymphocyte source, together with the high proliferative rate and potent anti-tumor activity of CIK cells, has allowed their use as immunotherapy in a wide variety of neoplasms. Cytotoxicity mediated by CD3+CD56+ T cells depends on the major histocompatibility antigen (MHC)-independent recognition of tumor cells and the activation of signaling pathways through the natural killer group 2 member D (NKG2D) cell-surface receptor. Clinical trials have demonstrated the feasibility and efficacy of CIK cell immunotherapy even in advanced stage cancer patients or those that have not responded to first-line treatment. This review summarizes biological and technical aspects of CIK cells, as well as past and current clinical trials and future trends in this form of immunotherapy.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	1776-2596 1776-260X
DOI:	10.1007/s11523-017-0489-2